TY - JOUR
T1 - CRISPR screen in regulatory T cells reveals modulators of Foxp3
AU - Cortez, Jessica T.
AU - Montauti, Elena
AU - Shifrut, Eric
AU - Gatchalian, Jovylyn
AU - Zhang, Yusi
AU - Shaked, Oren
AU - Xu, Yuanming
AU - Roth, Theodore L.
AU - Simeonov, Dimitre R.
AU - Zhang, Yana
AU - Chen, Siqi
AU - Li, Zhongmei
AU - Woo, Jonathan M.
AU - Ho, Josephine
AU - Vogel, Ian A.
AU - Prator, Grace Y.
AU - Zhang, Bin
AU - Lee, Youjin
AU - Sun, Zhaolin
AU - Ifergan, Igal
AU - Van Gool, Frédéric
AU - Hargreaves, Diana C.
AU - Bluestone, Jeffrey A.
AU - Marson, Alexander
AU - Fang, Deyu
N1 - Funding Information:
Competing interests T.L.R. is a cofounder of Arsenal Biosciences. A.M. is a cofounder, member of the Boards of Directors and a member of the Scientific Advisory Boards of Spotlight Therapeutics and Arsenal Biosciences. A.M. has served as an advisor to Juno Therapeutics, is a member of the scientific advisory board at PACT Pharma, and is an advisor to Trizell. A.M. owns stock in Arsenal Biosciences, Spotlight Therapeutics and PACT Pharma. The Marson lab has received sponsored research support from Juno Therapeutics, Epinomics and Sanofi, and gifts from Gilead and Anthem. J.A.B. is a cofounder of Sonoma BioTherapeutics; a stock holder and member of the Board of Directors on Rheos Medicines; and a stock holder and member of the Scientific Advisory Boards of Vir Therapeutics, Arcus Biotherapeutics, Solid Biosciences, and Celsius Therapeutics. J.A.B. owns stock in MacroGenics and Kadmon Holdings. A patent application has been filed based on the screen data described here.
Funding Information:
Acknowledgements We thank all members of the Marson lab as well as M. S. Anderson, K. M. Ansel, C. J. Ye, K. Schumann and L. Gilbert for helpful suggestions and technical advice; J. Freimer, S. Raju and E. Guo for helpful advice and assistance with the RNA-seq analysis pipeline; V. Nguyen, V. Tobin, R. Apathy, M. Nguyen, the UCSF Flow Cytometry Core, and N. Hah and G. Chou in the Salk NGS Core Facility for technical assistance; S. Pyle for assistance with graphics; and D. Nguyen for critical reading of the manuscript. D.F. is supported by NIH R01 grants (AI079056, AI108634 and CA232347). E.M. is supported by NIH F31 CA220801-03. J.T.C. is supported by the National Science Foundation Graduate Research Fellowship Program grant 1650113. J.G. was supported by the Salk Institute T32 Cancer Training Grant T32CA009370 and the NIGMS NRSA F32 GM128377-01. D.C.H. is supported by the National Institutes of Health (NIH) (GM128943-01, CA184043-03), the V Foundation for Cancer Research V2016-006, the Pew-Stewart Foundation for Cancer Research and the Leona M. and Harry B. Helmsley Charitable Trust. The Marson lab has received gifts from J. Aronov, G. Hoskin, K. Jordan, B. Bakar, the Caufield family and funds from the Innovative Genomics Institute (IGI), the Northern California JDRF Center of Excellence and the Parker Institute for Cancer Immunotherapy (PICI). A.M. holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund, is an investigator at the Chan–Zuckerberg Biohub and is a recipient of a The Cancer Research Institute (CRI) Lloyd J. Old STAR grant. This work used the Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley, supported by NIH S10 OD018174 Instrumentation Grant, the UCSF Flow Cytometry Core, supported by the Diabetes Research Center grants NIH P30 DK063720 and NIH S10 1S10OD021822-01, and the Salk NGS Core Facility, supported by the NIH-NCI CCSG: P30 014195, the Chapman Foundation and the Helmsley Charitable Trust.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/6/18
Y1 - 2020/6/18
N2 - Regulatory T (Treg) cells are required to control immune responses and maintain homeostasis, but are a significant barrier to antitumour immunity1. Conversely, Treg instability, characterized by loss of the master transcription factor Foxp3 and acquisition of proinflammatory properties2, can promote autoimmunity and/or facilitate more effective tumour immunity3,4. A comprehensive understanding of the pathways that regulate Foxp3 could lead to more effective Treg therapies for autoimmune disease and cancer. The availability of new functional genetic tools has enabled the possibility of systematic dissection of the gene regulatory programs that modulate Foxp3 expression. Here we developed a CRISPR-based pooled screening platform for phenotypes in primary mouse Treg cells and applied this technology to perform a targeted loss-of-function screen of around 500 nuclear factors to identify gene regulatory programs that promote or disrupt Foxp3 expression. We identified several modulators of Foxp3 expression, including ubiquitin-specific peptidase 22 (Usp22) and ring finger protein 20 (Rnf20). Usp22, a member of the deubiquitination module of the SAGA chromatin-modifying complex, was revealed to be a positive regulator that stabilized Foxp3 expression; whereas the screen suggested that Rnf20, an E3 ubiquitin ligase, can serve as a negative regulator of Foxp3. Treg-specific ablation of Usp22 in mice reduced Foxp3 protein levels and caused defects in their suppressive function that led to spontaneous autoimmunity but protected against tumour growth in multiple cancer models. Foxp3 destabilization in Usp22-deficient Treg cells could be rescued by ablation of Rnf20, revealing a reciprocal ubiquitin switch in Treg cells. These results reveal previously unknown modulators of Foxp3 and demonstrate a screening method that can be broadly applied to discover new targets for Treg immunotherapies for cancer and autoimmune disease.
AB - Regulatory T (Treg) cells are required to control immune responses and maintain homeostasis, but are a significant barrier to antitumour immunity1. Conversely, Treg instability, characterized by loss of the master transcription factor Foxp3 and acquisition of proinflammatory properties2, can promote autoimmunity and/or facilitate more effective tumour immunity3,4. A comprehensive understanding of the pathways that regulate Foxp3 could lead to more effective Treg therapies for autoimmune disease and cancer. The availability of new functional genetic tools has enabled the possibility of systematic dissection of the gene regulatory programs that modulate Foxp3 expression. Here we developed a CRISPR-based pooled screening platform for phenotypes in primary mouse Treg cells and applied this technology to perform a targeted loss-of-function screen of around 500 nuclear factors to identify gene regulatory programs that promote or disrupt Foxp3 expression. We identified several modulators of Foxp3 expression, including ubiquitin-specific peptidase 22 (Usp22) and ring finger protein 20 (Rnf20). Usp22, a member of the deubiquitination module of the SAGA chromatin-modifying complex, was revealed to be a positive regulator that stabilized Foxp3 expression; whereas the screen suggested that Rnf20, an E3 ubiquitin ligase, can serve as a negative regulator of Foxp3. Treg-specific ablation of Usp22 in mice reduced Foxp3 protein levels and caused defects in their suppressive function that led to spontaneous autoimmunity but protected against tumour growth in multiple cancer models. Foxp3 destabilization in Usp22-deficient Treg cells could be rescued by ablation of Rnf20, revealing a reciprocal ubiquitin switch in Treg cells. These results reveal previously unknown modulators of Foxp3 and demonstrate a screening method that can be broadly applied to discover new targets for Treg immunotherapies for cancer and autoimmune disease.
UR - http://www.scopus.com/inward/record.url?scp=85083990371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083990371&partnerID=8YFLogxK
U2 - 10.1038/s41586-020-2246-4
DO - 10.1038/s41586-020-2246-4
M3 - Article
C2 - 32499641
AN - SCOPUS:85083990371
SN - 0028-0836
VL - 582
SP - 416
EP - 420
JO - Nature
JF - Nature
IS - 7812
ER -